Megestrol Acetate Dispersible Tablets: New Hope for Cancer and Malnutrition Patients
[January 16, 2025] – Recently, Megestrol Acetate Dispersible Tablets, developed by a well-known pharmaceutical company in China, has been approved by the National Drug Administration (NMPA) for official launch.
The drug, as an innovative preparation, will play an important role in improving the treatment of malignant tumor-related cachexia, severe malnutrition, and specific endocrine diseases.
Progesterone Derivatives: Megestrol Acetate Dispersible Tablets
Medroxyprogesterone Acetate (MPA) is widely used for its unique hormone-modulating properties for a variety of indications, including advanced breast cancer, endometrial cancer, and cancer-related loss of appetite and weight loss. The launch of this dispersible tablet form further optimizes its dosing experience.
Pharmacology and Toxicology of Megestrol Acetate Dispersible Tablets
Megestrol Acetate Dispersible Tablets are a semi-synthetic progesterone derivative, which has a certain inhibitory effect on hormone-dependent tumors.
Its mechanism of action may be to control the development and growth of ovarian follicles through the effect on the secretion of pituitary gonadotropin, thus reducing the production of estrogen.
It acts on estrogen receptors, preventing their synthesis and reutilization, interfering with their binding to estrogen, and inhibiting the growth of tumor cells.
In addition, it also antagonizes the glucocorticoid receptor and interferes with the interaction between steroid hormone receptors and regulatory proteins associated with cell growth and differentiation.
In Indications and Clinical Significance
This medication is indicated for the management of malignant tumour-related cachexia, where it helps improve patients’ appetite, increase body weight, and significantly enhance the quality of life in those with advanced cancer.
It also shows good efficacy in addressing malnutrition and anorexia, particularly in patients whose appetite has been reduced due to disease or treatment.
Additionally, it is effective in treating specific endocrine disorders, including abnormal uterine bleeding in women and providing supportive care in the treatment of hormone-dependent tumours.
Market Prospects and Social Significance
With the increasing incidence of cancer and the emphasis on quality of life for cancer patients, the launch of megestrol acetate dispersible tablets not only fills the gaps in the existing treatment regimen, but also brings a better medication experience for patients.
Industry insiders expect that the drug will become an important product in the field of oncology supportive therapy, and is also expected to occupy a place in the international market in the future.
Conclusion
The use of the drug in adjuvant chemotherapy has also shown potential to reduce GI reactions and improve patient quality of life.
However, special caution is required for its use in specific populations such as pregnant and lactating women.
Overall, megestrol acetate dispersible tablets are promising for clinical use, but more studies are needed to explore their optimal use and long-term effects.
- However, DengYue‘s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it. So please feel free to inquiry us for Megestrol acetate dispersible tablets.
- Information from DengYueMedicne, China Medicine Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
